Articles By Jack Cush, MD
Monoarticular JIA - a Distinct Clinical Entity
Monoarticular Juvenile Idiopathic Arthritis (monoJIA) is typically classified under oligoarticular JIA, but a recent study suggests it is a separate entity.
Read Article
Pizza and Rheumatoid Arthritis (8.11.2023)
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
Read Article
Colchicine or Prednisone in CPPD?
The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.
Read Article
Patient Perspectives on Telemedicine Use During the Pandemic
Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients.
Read Article
Postural Orthostatic Tachycardia Syndrome Review
The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.
Read Article
English for the Biologically-Challenged (8.4.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.
Read Article
Antenatal Corticosteroids and Serious Infection in Offspring
A claims data study shows that maternal use of antenatal corticosteroids may be associated with an increased risk of serious infection in the offspring's first 12 months.
Read Article
2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
Read Article
Bifunctional B-cell Targeted Therapy in IgG4-related Disease
A novel B-cell depletion trial, using obexelimab (a bifunctional, monoclonal antibody that binds CD19 and Fc gamma receptor IIb), has shown efficacy and safety in patients with active IgG4-related disease.
Read Article
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with polymyalgia rheumatica (PMR).
Read Article
